Selank is a synthetic heptapeptide developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. Its research profile centres on anxiolytic and cognitive effects, with a body of published work that also addresses immune modulation. N-Acetyl Selank Amidate is a chemically modified form of the base compound — incorporating terminal group modifications that significantly improve stability, resistance to enzymatic degradation, and biological half-life.
This article covers what Selank is, how the amidate form differs, the mechanisms proposed in the research, what the published studies show, and what researchers working with it need to know.
01 — What Is Selank?
Selank (TBIO6) is a synthetic analogue of Tuftsin, an endogenous immunopeptide. Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) produced by the spleen through enzymatic cleavage of the Fc region of IgG, with known roles in immune regulation and phagocyte activation.
Selank extends this base sequence to a heptapeptide — Thr-Lys-Pro-Arg-Pro-Gly-Pro — adding three amino acids that substantially alter its pharmacological profile, receptor interactions, and metabolic stability relative to Tuftsin. It was developed in the late 1990s by Neznamov and colleagues and has been examined through clinical trials conducted under the Russian Ministry of Health, where it received registration as an anxiolytic agent.
What the Amidate Form Adds
N-Acetyl refers to the addition of an acetyl group at the N-terminus of the peptide. Amidate refers to amidation of the C-terminus — replacing the terminal carboxylic acid group with an amide group (-CONH₂).
Both modifications protect the peptide from exopeptidase activity — enzymes that degrade peptides by sequentially cleaving terminal amino acids. By capping both ends of the molecule, N-Acetyl Selank Amidate resists this degradation and achieves a meaningfully longer half-life than base Selank. The amidate form also demonstrates enhanced receptor binding affinity in research contexts, meaning a smaller quantity of compound is required to achieve equivalent biological interaction. For researchers, this translates to a more stable and more active compound under the same experimental conditions.
02 — Proposed Mechanisms
GABAergic Modulation
The primary mechanism associated with Selank's anxiolytic effects in the research literature is modulation of the GABAergic system. Research has shown that Selank enhances GABA-A receptor activity, increasing inhibitory neurotransmission in a manner that parallels benzodiazepine effects mechanistically, but through a distinct binding site. Notably, the research data does not show the receptor downregulation and tolerance development observed with classical benzodiazepines — a finding that distinguishes Selank's profile from standard GABAergic anxiolytics in animal models.
BDNF Upregulation
Published studies have shown that Selank upregulates brain-derived neurotrophic factor (BDNF) in relevant brain regions. BDNF is a key mediator of neuroplasticity, learning, and memory consolidation. Its upregulation is proposed as the mechanism underlying Selank's cognitive-enhancing effects — observed alongside, and potentially independent of, its anxiolytic activity.
Enkephalin System Interaction
Research has documented Selank's interaction with the endogenous opioid (enkephalin) system. The compound appears to inhibit enkephalin-degrading enzymes, extending the activity of natural enkephalins involved in stress response and mood regulation. This mechanism is proposed as complementary to GABAergic modulation and may account for qualitative differences in Selank's anxiolytic profile compared to classical GABA agonists.
Immune Modulation
As a Tuftsin analogue, Selank retains immunomodulatory properties. Research has documented effects on interleukin expression — specifically modulation of IL-6 and related pro-inflammatory cytokines — suggesting relevance in neuroinflammatory and stress-immune interaction research. This immune-active profile distinguishes Selank from purely GABAergic compounds and connects it to a broader research context involving the interaction between anxiety, stress, and immune function.
03 — What the Published Research Shows
Anxiety and Stress Models
The Russian clinical literature on Selank includes controlled trials in patients with generalised anxiety disorder and anxiety-asthenic syndrome. These trials reported significant reductions in anxiety measures compared to placebo, with an effect profile described as sustained across the study period. The absence of tolerance development across these trial durations is a notable finding in a compound acting on the GABAergic system, though the limitation of independent replication applies (see below).
Cognitive Effects
Multiple animal studies and limited clinical observations have documented cognitive enhancement with Selank — specifically improvements in working memory, attention, and learning in both normal and cognitively stressed subjects. The BDNF upregulation mechanism provides a plausible basis for these effects. This dual anxiolytic-cognitive profile is a key feature of the compound's research interest.
Immune Parameters
Studies have examined Selank's effects on immune function in animal models of chronic stress and immunocompromised states. Results indicate modulation of lymphocyte activity and normalisation of cytokine profiles disrupted by chronic stress — consistent with its Tuftsin-based lineage and the known interaction between the stress response and immune function.
04 — Administration in Research: The Intranasal Route
A distinctive feature of Selank in research contexts is its common administration via the intranasal route. The intranasal pathway provides direct access to the central nervous system through the olfactory epithelium, bypassing the blood-brain barrier — relevant for a CNS-active compound where systemic metabolism would otherwise reduce CNS bioavailability.
The amidate modification is particularly valuable for intranasal research protocols. Mucosal surfaces are rich in peptidases that rapidly degrade unprotected peptides. The N-acetyl and amidate modifications significantly improve resistance to this enzymatic environment, allowing more of the administered compound to reach the CNS intact.
Selank can also be examined via subcutaneous routes in animal models. The appropriate administration route and vehicle for any research protocol should be defined by the study design and all applicable regulations.
05 — What Is Not Yet Established
Geographic concentration of research — the substantial majority of published Selank studies originate from Russian research institutions and have not been independently replicated in large-scale international trials. This is the most significant limitation of the evidence base
N-Acetyl Selank Amidate specifically has limited direct published literature — most available data applies to base Selank; the degree to which the modified form produces proportionally or qualitatively different effects requires further characterisation
Long-term safety data from controlled research is not available for either form
Optimal research parameters — concentration, administration route, frequency — have not been established in standardised, published protocols
06 — Research Formats
N-Acetyl Selank Amidate is available as a lyophilised powder for research applications. For intranasal protocols, it is typically reconstituted in bacteriostatic water or sterile saline; the appropriate vehicle depends on the specific administration method and model being used.
